Scarica l'app Stockscreener
3.06
2.86%
-0.09
Dopo l'orario di chiusura:
3.06
Precedente Chiudi:
$3.15
Aprire:
$3.02
Volume 24 ore:
4.67M
Relative Volume:
1.30
Capitalizzazione di mercato:
$468.25M
Reddito:
$2.80M
Utile/perdita netta:
$-115.18M
Rapporto P/E:
-3.6115
EPS:
-0.8473
Flusso di cassa netto:
$-94.03M
1 W Prestazione:
+6.25%
1M Prestazione:
+9.29%
6M Prestazione:
-13.80%
1 anno Prestazione:
+23.39%
Intervallo 1D:
$2.96
$3.285
Intervallo di 1 settimana:
$2.71
$3.285
Portata 52W:
$2.01
$5.228
Absci Corp Stock (ABSI) Company Profile
Nome
Absci Corp
Settore
Industria
Telefono
(360) 949-1041
Indirizzo
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.06 | 468.25M | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | Iniziato | JP Morgan | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-01-22 | Iniziato | Needham | Buy |
| 2024-10-02 | Iniziato | Guggenheim | Buy |
| 2024-07-03 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Iniziato | Truist | Buy |
| 2022-03-02 | Ripresa | Cowen | Market Perform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-11-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-08-16 | Iniziato | BofA Securities | Neutral |
| 2021-08-16 | Iniziato | Cowen | Market Perform |
| 2021-08-16 | Iniziato | Credit Suisse | Outperform |
| 2021-08-16 | Iniziato | Stifel | Hold |
Mostra tutto
Absci Corp Borsa (ABSI) Ultime notizie
Highs Report: Can Absci Corporation lead its sector in growth2026 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Update Recap: Is Absci Corporation a top pick in the sectorWeekly Trade Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Is now the right time to enter Absci CorporationQuarterly Growth Report & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Targets Report: Will Absci Corporation benefit from government policy2026 Weekly Recap & Weekly High Potential Stock Alerts - baoquankhu1.vn
Insider Trends: Will Absci Corporation benefit from government policy2026 Breakouts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Absci Corp. Earnings Call: Betting on ABS-201 - TipRanks
Redmile Group (ABSI) reports 5.4% Absci stake as share count rises - Stock Titan
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Vanguard affiliates to report separately as ABSI holdings shift (ABSI) - Stock Titan
Here's Why We're Watching Absci's (NASDAQ:ABSI) Cash Burn Situation - finance.yahoo.com
What is HC Wainwright's Forecast for Absci FY2030 Earnings? - marketbeat.com
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $4.2 to $8 - 富途牛牛
Absci Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00 - GuruFocus
Absci Shares Fall on Wider 4Q Loss, Lower Revenue - news.futunn.com
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
Absci reports Q4 EPS (20c), consensus (17c) - TipRanks
Absci’s AI-Native Integrated Drug Creation Platform: Advancing Antibody Therapeutics and Biopharma Innovation - Minichart
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions - Bitget
Absci Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips - Investing.com
Absci Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data - Stock Titan
Absci earnings missed by $0.02, revenue fell short of estimates - Investing.com
Absci (NASDAQ:ABSI) Announces Quarterly Earnings Results - MarketBeat
Absci shares slip nearly 4% on Q4 revenue miss, wider loss than expected - Investing.com
Absci 10-K: Partner revenue $2.8M, Net loss $115.2M, EPS $(0.84) - TradingView
ABSCI ($ABSI) Releases Q4 2025 Earnings - Quiver Quantitative
Absci (NASDAQ: ABSI) highlights ABS-201 trial progress and AI drug platform - Stock Titan
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results - globenewswire.com
AbSci Corp options imply 13.4% move in share price post-earnings - TipRanks
Absci forms advisory board for endometriosis drug program - investing.com
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - The Manila Times
Absci forms advisory board for endometriosis drug program By Investing.com - Investing.com Canada
Absci taps Yale, Mayo experts for non-hormonal endometriosis drug - Stock Titan
Earnings Scheduled For March 24, 2026 - Benzinga
Earnings To Watch: Absci Corp (ABSI) Reports Q4 2025 Result - GuruFocus
ABSI Technical Analysis | Trend, Signals & Chart Patterns | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Absci Corp Azioni (ABSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):